Skip to main
IRD
IRD logo

Opus Genetics (IRD) Stock Forecast & Price Target

Opus Genetics (IRD) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Opus Genetics Inc. is positioned favorably in the biopharmaceutical sector, particularly with its promising pipeline of gene therapies targeting inherited retinal diseases and other retinal disorders. The company has recently demonstrated significant efficacy in its clinical trials, notably with phentolamine achieving positive primary endpoints in both presbyopia and keratorefractive surgery, which bolsters investor confidence in its upcoming market entries. Additionally, Opus has secured non-dilutive funding totaling up to $3.6 million for its preclinical programs, allowing it to advance its initiatives while minimizing shareholder dilution and optimizing capital allocation.

Bears say

Opus Genetics Inc. has reported a decrease in R&D expenses, totaling $6.4 million for the quarter, down from $9.0 million a year ago, indicating a potential reduction in investment aimed at advancing its pipeline. The company has also consistently incurred significant losses since its inception, which raises concerns about its financial sustainability and long-term viability. Additionally, increasing market competition from emerging therapies targeting similar ophthalmic conditions may hinder Opus's ability to penetrate the market effectively and manage pricing, further exacerbating its negative financial outlook.

Opus Genetics (IRD) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Opus Genetics (IRD) Forecast

Analysts have given Opus Genetics (IRD) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Opus Genetics (IRD) has a Strong Buy consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Opus Genetics (IRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.